The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes

Clinical Therapeutics

Volumn 39, Issue 3, 2017, Pages 477-486

  Chavarria, Victor ^a   Vian, João ^b,c   Pereira, Círia ^b,c   Data Franco, João ^c,d   Fernandes, Brisa S ^e,f   Berk, Michael ^e,g,h,i   Dodd, Seetal ^e,g,h,i  

^a Linea Primaria Salut Mental   (Spain)

^b Centro Hospitalar Lisboa Norte   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d Orthopedic Surgery Department   (Portugal)

^e DEAKIN UNIVERSITY   (Australia)

^f FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^g BARWON HEALTH   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

adverse effects; clinical trial; nocebo; pharmacology; placebo; treatment

Indexed keywords

PLACEBO;

CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG EFFECT; HUMAN; NOCEBO EFFECT; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADVERSE DRUG REACTION;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NOCEBO EFFECT; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85013471866     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.01.031     Document Type: Review

References (73)

1. 1 Kerr, C.E., Milne, I., Kaptchuk, T.J., William Cullen and a missing mind-body link in the early history of placebos. J R Soc Med 101 (2008), 89–92.
2. 2 Kaptchuk, T.J., Kerr, C.E., Zanger, A., Placebo controls, exorcisms, and the devil. Lancet 374 (2009), 1234–1235.
3. 3 Crichton, F., Petrie, K.J., Accentuate the positive: counteracting psychogenic responses to media health messages in the age of the Internet. J Psychosom Res 79 (2015), 185–189.
4. 4 Webster, R.K., Weinman, J., Rubin, G.J., A systematic review of factors that contribute to nocebo effects. Heal Psychol 35 (2016), 1334–1355.
5. 5 Szemerszky, R., Dömötör, Z., Berkes, T., Köteles, F., Attribution-based nocebo effects. perceived effects of a placebo pill and a sham magnetic field on cognitive performance and somatic symptoms. Int J Behav Med 23 (2016), 204–213.
6. 6 Finniss, D.G., Kaptchuk, T.J., Miller, F., Benedetti, F., Placebo effects: biologival, clinical and ethical advances. Lancet 375 (2010), 686–695.
7. 7 Fields, H.L., Neurophysiology of pain and pain modulation. Am J Med 77 (1984), 2–8.
8. 8 Voudouris, N.J., Peck, C.L., Coleman, G., The role of conditioning and verbal expectancy in the placebo response. Pain 43 (1990), 121–128.
9. 9 Benedetti, F., Rainero, I., Pollo, A., New insights into placebo analgesia. Curr Opin Anaesthesiol 16 (2003), 515–519.
10. 10 Kong, J., Spaeth, R., Cook, A., et al. Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. PLoS ONE, 2013, 8.
11. 11 Hall, K.T., Lembo, A.J., Kirsch, I., et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE, 2012, 7.
12. 12 Bartels, D.J., Van Laarhoven, A.I., Haverkamp, E.A., et al. Role of conditioning and verbal suggestion in placebo and nocebo effects on itch. PLoS ONE, 2014, 9.
13. 13 Bartels, D.J., Van Laarhoven, A.I., Van De Kerkhof, P.C., Evers, A.W., Placebo and nocebo effects on itch: effects, mechanisms, and predictors. Eur J Pain (United Kingdom) 20 (2016), 8–13.
14. 14 Napadow, V., Li, A., Loggia, M.L., et al. The imagined itch: brain circuitry supporting nocebo-induced itch in atopic dermatitis patients. Allergy Eur J Allergy Clin Immunol 70 (2015), 1485–1492.
15. 15 Kirsch, I., Antidepressants and the placebo effect. Zeitschrift fur Psychol/J Psychol 222 (2014), 128–134.
16. 16 Price, D.D., Finniss, D.G., Benedetti, F., A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 59 (2008), 565–590.
17. 17 Price, D.D., Milling, L.S., Kirsch, I., et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83 (1999), 147–156.
18. 18 Amanzio, M., Benedetti, F., Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19 (1999), 484–494.
19. 19 Reicherts, P., Gerdes, A.B., Pauli, P., Wieser, M.J., Psychological placebo and nocebo effects on pain rely on expectation and previous experience. J Pain 17 (2016), 203–214.
20. 20 Petrie, K.J., Broadbent, E.A., Kley, N., et al. Worries about modernity predict symptom complaints after environmental pesticide spraying. Psychosom Med 67 (2005), 778–782.
21. 21 Colloca, L., Miller, F.G., The nocebo effect and its relevance for clinical practice. Psychosom Med 73 (2011), 598–603.
22. 22 Enck, P., Bingel, U., Schedlowski, M., Rief, W., The placebo response in medicine: minimize, maximize or personalize?. Nat Rev Drug Discov 12 (2013), 191–204.
23. 23 Finniss, D.G., Benedetti, F., Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 114 (2005), 3–6.
24. 24 Colloca, L., Benedetti, F., Placebos and painkillers: is mind as real as matter?. Nat Rev Neurosci 6 (2005), 545–552.
25. 25 Dodd, S., Dean, O., Vian, J., Berk, M., A review of the theoretical and biological understanding of nocebo and placebo phenomena. Clin Ther, 39, 2017.
26. 26 Benedetti, F., Amanzio, M., Vighetti, S., Asteggiano, G., The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 26 (2006), 12014–12022.
27. 27 Curie, A., Yang, K., Kirsch, I., et al. Placebo responses in genetically determined intellectual disability: a meta-analysis. PLoS ONE 10 (2015), 1–16.
28. 28 Lachman, H.M., Papolos, D.F., Saito, T., et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996), 243–250.
29. 29 Furmark, T., Appel, L., Henningsson, S., et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 28 (2008), 13066–13074.
30. 30 Sherman, R., Hickner, J., Academic physicians use placebos in clinical practice and believe in the mind-body connection. J Gen Intern Med 23 (2008), 7–10.
31. 31 Howick, J., Bishop, F.L., Heneghan, C., et al. Placebo use in the United Kingdom: results from a national survey of primary care practitioners. PLoS ONE 8 (2013), 1–6.
32. 32 Vickers, A.J., Clinical trials of homeopathy and placebo: analysis of a scientific debate. J Altern Complement Med 6 (2000), 49–56.
33. 33 Pollo, A., Amanzio, M., Arslanian, A., et al. Response expectancies in placebo analgesia and their clinical relevance. Pain 93 (2001), 77–84.
34. 34 Atlas, L.Y., Whittington, R.A., Lindquist, M.A., et al. Dissociable influences of opiates and expectations on pain. J Neurosci 32 (2012), 8053–8064.
35. 35 Levine, J.D., Gordon, N.C., Influence of the method of drug administration on analgesic response. Nature 312 (1984), 755–756.
36. 36 Testa, M., Rossettini, G., Enhance placebo, avoid nocebo: how contextual factors affect physiotherapy outcomes. Man Ther 24 (2016), 65–74.
37. 37 Kirsch, I., Sapirstein, G., Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat 1 (1998), 1–16.
38. 38 Khan, A., Warner, H.A., Brown, W.A., Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57 (2000), 311–317.
39. 39 Beutler, L.E., Prozac and placebo: there's a pony in there somewhere. Prev Treat, 1, 1998 No.
40. 40 Klein, D.F., Listening to meta-analysis but hearing bias. Prev Treat, 1, 1998 Article 6c.
41. 41 Kirsch, I., Moore, T.J., Scoboria, A., Nicholls, S., The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 5 (2002), 1–11.
42. 42 Rabkin, J.G., Markowitz, J.S., Stewart, J., et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 19 (1986), 75–86.
43. 43 Rutherford, B.R., Sneed, J.R., Roose, S.P., Does study design influence outcome?. Psychother Psychosom 78 (2009), 172–181.
44. 44 Walsh, B.T., Seidman, S.N., Sysko, R., Gould, M., Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002), 1840–1847.
45. 45 Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5 (2008), 0260–0268.
46. 46 Furukawa, T.A., Cipriani, A., Atkinson, L.Z., et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. The Lancet Psychiatry 3 (2016), 1059–1066.
47. 47 Jewell, N.P., Natural history of diseases: statistical designs and issues. Clin Pharmacol Ther 100 (2016), 353–361.
48. 48 Rutherford, B.R., Sneed, J.R., Roose, S.P., Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis. J Affect Disord 140 (2012), 57–65.
49. 49 Furukawa, T.A., Noma, H., Caldwell, D.M., et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 130 (2014), 181–192.
50. 50 Barefoot, J.C., Brummett, B.H., Williams, R.B., et al. Recovery expectations and long-term prognosis of patients with coronary heart disease. Arch Intern Med 171 (2011), 929–935.
51. 51 Kaptchuk, T.J., Friedlander, E., Kelley, J.M., et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5, 2010.
52. 52 Sandler, A.D., Glesne, C.E., Bodfish, J.W., Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. J Dev Behav Pediatr 31 (2010), 369–375.
53. 53 Ader, R., Mercurio, M.G., Walton, J., et al. Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med 72 (2010), 192–197.
54. 54 Huskisson, E.C., Simple analgesics for arthritis. Br Med J 4 (1974), 196–200.
55. 55 Fässler, M., Meissner, K., Kleijnen, J., et al. A systematic review found no consistent difference in effect between more and less intensive placebo interventions. J Clin Epidemiol 68 (2015), 442–451.
56. 56 Posternak, M.A., Zimmerman, M., Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 190 (2007), 287–292.
57. 57 Weimer, K., Colloca, L., Enck, P., Placebo effects in psychiatry: mediators and moderators. The Lancet Psychiatry 2 (2015), 246–257.
58. 58 Newcorn, J.H., Sutton, V.K., Zhang, S., et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 48 (2009), 1165–1172.
59. 59 Cohen, D., Consoli, A., Bodeau, N., et al. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol 20 (2010), 39–47.
60. 60 Muthen, B., Brown, H.C., Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med 28 (2009), 3363–3385.
61. 61 Papakostas, G.I., Fava, M., Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19 (2009), 34–40.
62. 62 Quigley, E.M.M., Tack, J., Chey, W.D., et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C—a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 37 (2013), 49–61.
63. 63 Mallinckrodt, C., Chuang-Stein, C., McSorley, P., et al. A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant. Pharm Stat 6 (2007), 9–22.
64. 64 Suchman, A.L., Ader, R., Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 52 (1992), 372–377.
65. 65 Zelen, M., A new design for randomized clinical trials. N Engl J Med 300 (1979), 1242–1245.
66. 66 Woods, S.W., Gueorguieva, R.V., Baker, C.B., Makuch, R.W., Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 62 (2005), 961–970.
67. 67 Rief, W., Nestoriuc, Y., Weiss, S., et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 118 (2009), 1–8.
68. 68 Hróbjartsson, A., Gøtzsche, P.C., Placebo interventions for all clinical conditions. Cochrane Database Syst Rev, 20, 2010, CD003974.
69. 69 Faasse, K., Grey, A., Jordan, R., et al. Seeing is believing: impact of social modeling on placebo and nocebo responding. Heal Psychol 34 (2015), 880–885.
70. 70 Rheker, J., Winkler, A., Doering, B.K., Rief, W., Learning to experience side effects after antidepressant intake—results from a randomized, controlled, double-blind study. Psychopharmacology (Berl) 234 (2017), 329–338.
71. 71 Edwards, A., Elwyn, G., Covey, J., et al. Presenting risk information—a review of the effects of “framing” and other manipulations on patient outcomes. J Health Commun 6 (2001), 61–82.
72. 72 Di Blasi, Z., Harkness, E., Ernst, E., et al. Influence of context effects on health outcomes: a systematic review. Lancet 357 (2001), 757–762.
73. 73 Data-Franco, J., Berk, M., The nocebo effect: a clinicians guide. Aust N Z J Psychiatry 47 (2013), 617–623.